By Colin Kellaher
BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study.
BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab after the oncology company determined that the study was unlikely to meet its primary endpoint of overall survival.
BeiGene in late 2021 inked an option, collaboration and license agreement for ociperlimab with Novartis that included an upfront payment of $300 million from the Swiss drugmaker.
However, the companies in 2023 agreed to terminate the deal, with all rights to ociperlimab returning to BeiGene.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 03, 2025 06:34 ET (10:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.